Talk Title: Large scale production of highly cytotoxic human NK cells for therapeutic use by leveraging innate biology

Hugh Brady is a Professor of Immunology in the Department of Life Sciences at Imperial College London and CSO of NK:IO Ltd (https://nk-io.com/), an Imperial spin-out company developing allogeneic natural killer (NK) cell therapies.